Riding the personalized medicine wave, AssureRx Health Inc. has found a lead investor for a Series A investment round that it hopes reaches $10 million.
The Cincinnati-area company — which sells a genetic test that helps doctors pick the right psychiatric drugs for patients, based on their genes — has raised nearly $8 million in angel funding since it was launched five years ago, VentureWire reported.
The amount of funding the company has already raised for its Series A and the identity of the lead investor are unclear. CEO James Burns didn’t immediately return a call.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
In 2009, AssureRx launched its first test, GeneSightRx, which uses a cheek swab, mathematical algorithms and bioinformatics to narrow drug choices to those that work with a patient’s genes. Last year, Burns pegged the test’s annual market at $3 billion, and that’s “on the low end,” he said.
AssureRx initially is targeting neuro-psychiatric and neuro-behavioral disorders because they represent the largest unmet patient need. Future products might include tests that help doctors choose medications for patients who have neuro-degenerative diseases like Alzheimer’s or Parkinson’s, as well as disorders such as attention-deficit hyperactivity and post-traumatic stress.
Cincinnati Children’s Hospital Medical Center and Mayo Clinic are equity holders and technology collaborators. Other investors include Queen City Angels, CincyTech, the Health Foundation of Greater Cincinnati, and Blue Chip Venture.
Burns shared his growth plans for the company in a December article in the Cincinnati Business Courier. AssureRx could have 40 employees by the end of the year, up from the current 16. Within three years, the company could have 100 employees, Burns said.
A Personalized Approach to Medication Nonadherence
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
The company could be profitable within two years, and Burns hopes that its annual revenues reach $25 million within three years.
